title: Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions.
abstract: We treated a 57-year-old woman for refractory inflammatory bowel disease with a humanized anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). The patient also had a 15-year history of Crohn's disease and a 20-year history of moderate to severe psoriasis. She received a single infusion of Infliximab (5 mg/kg). Two weeks after the infusion her psoriasis had dramatically improved in appearance. To our knowledge, our case is the first reported instance of successful anti-tumor necrosis factor alpha therapy in psoriasis.
authors.affiliation: Divisions of Clinical Pharmacology and Gastroenterology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Oh
authors.forename: K M
authors.initials: KM
authors.lastname: Das
authors.forename: A B
authors.initials: AB
authors.lastname: Gottlieb
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications / Q000628:therapy; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000473:pathology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab